Internal Medicine News - Generic carvedilol formulations
The first generic formulations of the [beta]-blocker carvedilol (Coreg) have been approved by the Food and Drug Administration for treating hypertension, mild to severe chronic heart failure, and left ventricular dysfunction following a myocardial infarction in clinically stable patients. Available in four strengths–3.125 mg, 6.25 mg, 12.5 mg, and 25 mg–the tablets are made by these companies: Actavis Elizabeth LLC, Apotex Inc., Aurobindo Pharma Ltd., Caraco Pharmaceutical Laboratories Ltd., Dr.
Related Results
Trial data added to coreg labelNew indications for once-daily CoregFlamel Technologies Welcomes FDA Approval of COREG CR™Flamel Technologies Welcomes Nationwide Availability of COREG CR™New & approved: Coreg biotronik home monitoring system
Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Ltd., Sandoz Inc., Taro Pharmaceutical Industries Ltd., TEVA Pharmaceuticals USA, Watson Laboratories Inc., and Zydus Pharmaceuticals (USA) Inc.
COPYRIGHT 2007 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
